Christian Taucher
Overview
Explore the profile of Christian Taucher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abedian S, Taucher C, Perscha S, Djuris M, Hussein R, Hanke S
Stud Health Technol Inform
. 2024 Aug;
316:437-441.
PMID: 39176771
In recent years, the adoption of wearable gadgets such as Fitbit has revolutionized the way individuals track and monitor their personal activity data. These devices provide valuable in-sights into an...
2.
Talaat K, Porter C, Chakraborty S, Feijoo B, Brubaker J, Adjoodani B, et al.
Microorganisms
. 2024 Apr;
12(4).
PMID: 38674674
Controlled human infection models are important tools for the evaluation of vaccines against diseases where an appropriate correlate of protection has not been identified. Enterotoxigenic (ETEC) strain LSN03-016011/A (LSN03) is...
3.
Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, et al.
J Infect
. 2023 Jul;
87(3):242-254.
PMID: 37406777
Objectives: Booster doses for COVID-19 vaccinations have been shown to amplify the waning immune response after primary vaccination and to enhance protection against emerging variants of concern (VoCs). Here, we...
4.
Lazarus R, Querton B, Ramljak I, Dewasthaly S, Jaramillo J, Dubischar K, et al.
Lancet Infect Dis
. 2022 Sep;
22(12):1716-1727.
PMID: 36075233
Background: The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna, Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to assess the safety and immunogenicity of primary vaccination with VLA2001...
5.
Lazarus R, Taucher C, Brown C, Ramljak I, Danon L, Dubischar K, et al.
J Infect
. 2022 Jun;
85(3):306-317.
PMID: 35718205
Objectives: We aimed to evaluate the safety and optimal dose of a novel inactivated whole-virus adjuvanted vaccine against SARS-CoV-2: VLA2001. Methods: We conducted an open-label, dose-escalation study followed by a...
6.
Lamarche L, Taucher C
Can Pharm J (Ott)
. 2020 Mar;
153(2):72-73.
PMID: 32206147
No abstract available.
7.
Taucher C, Barnett E, Cramer J, Eder-Lingelbach S, Jelinek T, Kadlecek V, et al.
Travel Med Infect Dis
. 2020 Mar;
34:101616.
PMID: 32156630
Background: In an initial study among children from non-Japanese encephalitis (JE)-endemic countries, seroprotection rates remained high 6 months after completion of the primary series with IXIARO®. Methods: In this open-label...
8.
Taucher C, Kollaritsch H, Dubischar K
Vaccine
. 2019 Apr;
37(19):2529-2531.
PMID: 30962094
Immunization with the Japanese encephalitis (JE) vaccine IXIARO® results in protective neutralizing antibody levels for one year. Since persistence of protective titer levels beyond one year was unknown, a 5 ...
9.
Kadlecek V, Borja-Tabora C, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan Jr B, et al.
Pediatr Infect Dis J
. 2018 Jun;
37(9):e233-e240.
PMID: 29912844
Background: An inactivated Vero cell culture derived Japanese encephalitis virus vaccine (IXIARO) requires a booster dose 1 year after primary schedule for long-term antibody persistence in adults. The aim of...
10.
Jelinek T, Cromer M, Cramer J, Mills D, Lessans K, Gherardin A, et al.
Travel Med Infect Dis
. 2018 Mar;
22:18-24.
PMID: 29549036
Background: Young travelers to South-East Asia may be at risk for Japanese encephalitis (JE). Methods: IXIARO (0.25 ml or 0.5 ml, depending on age) were administrated to 100 travelers aged ...